^
9h
IL-1α facilitates GSH synthesis to counteract oxidative stress in oral squamous cell carcinoma under glucose-deprivation. (PubMed, Cancer Lett)
The intratumoral administration of siRNAs against IL1A mRNA markedly reversed GSH production and sensitized OSCC cells to Anlotinib in HN6 xenograft models. Overall, the current study demonstrates novel evidence that the autocrine IL-1α favors endogenous anti-oxidative process and confers therapeutic resistance to nutrition-starvation in OSCCs.
Journal
|
IL1A (Interleukin 1, alpha)
|
Focus V (anlotinib)
10h
Pharmacological blockade of HDAC6 attenuates cancer progression by inhibiting IL-1β and modulating immunosuppressive response in OSCC. (PubMed, Int Immunopharmacol)
Nocodazole pre-treatment proved that TSA inhibited the lysosomal exocytosis of IL-1β through tubulin acetylation. In conclusion, HDAC6 inhibitors attenuated TME and cancer progression through the regulation of IL-1β in OSCC.
Journal
|
HDAC6 (Histone Deacetylase 6) • ITGAM (Integrin, alpha M) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1) • CASP1 (Caspase 1)
|
HDAC6 expression
14h
Association of COX-2, TNF-α, TLR4, and IKKα With Survival of Patients With Oral Squamous Cell Carcinomas: A Systematic Review. (PubMed, Asian Pac J Cancer Prev)
COX-2 overexpression may be associated with a poorer prognosis in oral SCC. The insufficiency of studies about TNF-α, TLR4, and IKKα restrained their validation as predictors of prognosis.
Review • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • TLR4 (Toll Like Receptor 4)
14h
High P16INK4A Expression, Keratinizing Features, and Surgical Margin-Free Status are Associated with Improved Survival in Patients with Oral Squamous Cell Carcinomas. (PubMed, Asian Pac J Cancer Prev)
P16INK4A positive staining, early stages, negative cervical lymph node infiltration, and free-surgical margins are associated with better prognosis in OSCC patients. The study emphasizes the importance of early detection and the potential use of p16INK4A and other clinical variables to stratify OSCC patients with high risks of recurrence and worse overall survivals.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
CDKN2A expression
14h
Understanding exososmes: Part 3-therapeutic + diagnostic potential in dentistry. (PubMed, Periodontol 2000)
In total 47 diagnostic studies revealed a role for salivary/crevicular fluid exosomes for the diagnosis of birth defects, cardiovascular disease, diabetes, gingival recession detection, gingivitis, irritable bowel syndrome, neurodegenerative disease, oral lichen planus, oral squamous cell carcinoma, oropharyngeal cancer detection, orthodontic root resorption, pancreatic cancer, periodontitis, peri-implantitis, Sjögren syndrome, and various systemic diseases. Hence, we characterize the exosomes as possessing "remarkable" potential, serving as a valuable tool for clinicians with significant advantages.
Review • Journal
|
BMP2 (Bone Morphogenetic Protein 2)
23h
SP1 Gene Methylation in Head and Neck Squamous Cell Cancer in HPV-Negative Patients. (PubMed, Genes (Basel))
The methylation of the SP1 gene in tumor DNA suppresses its expression, hinders HNSCC cell proliferation regulation, and could be a molecular indicator of malignant cell growth. The study of DNA methylation of various genes involved in carcinogenesis is promising because hypermethylated promoters can serve as potential biomarkers of disease.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SMAD3 (SMAD Family Member 3) • SP1 (Sp1 Transcription Factor)
23h
Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy. (PubMed, Biomedicines)
The combinatorial efficacy of volasertib and radiotherapy was replicated in xenograft mouse models. These findings highlight the potential of adding PLK-1 inhibitors to adjuvant therapy regimens in OSCC.
Journal
|
PLK1 (Polo Like Kinase 1)
|
volasertib (NBL-001)
1d
Synthetic Circular RNA for microRNA-1269a Suppresses Tumor Progression in Oral Squamous Cell Carcinoma. (PubMed, Cancers (Basel))
In particular, phospholipase C gamma 2 (PLCG2), which is related to OSCC clinical stage and overall survival, was affected by the circRNA-1269a/miR-1269a axis. Taken together, synthetic circRNA-1269a inhibits tumor progression via miR-1269a and its downstream targets, indicating that artificial circRNAs could represent an effective OSCC therapeutic.
Journal • Circular RNA
|
PLCG2 (Phospholipase C Gamma 2) • MIR1269A (MicroRNA 1269a)
1d
EMT Dynamics in Lymph Node Metastasis of Oral Squamous Cell Carcinoma. (PubMed, Cancers (Basel))
Our findings demonstrate that EMT marker expression correlates with lymph node metastasis in OSCC. Developing therapies targeting regulators such as N-cadherin may prevent metastasis and improve outcomes.
Journal
|
CDH1 (Cadherin 1) • TGFB1 (Transforming Growth Factor Beta 1) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2)
1d
Analysis of the effect of CCR7 on the microenvironment of mouse oral squamous cell carcinoma by single-cell RNA sequencing technology. (PubMed, J Exp Clin Cancer Res)
CCR7 gene knockout can significantly inhibit the growth of mouse oral squamous cell carcinoma by promoting the polarization of M2 macrophages.
Preclinical • Journal
|
CCR7 (Chemokine (C-C motif) receptor 7) • DUSP1 (Dual Specificity Phosphatase 1)
1d
Chemerin promotes invasion of oral squamous cell carcinoma by stimulating IL-6 and TNF-α production via STAT3 activation. (PubMed, Mol Biol Rep)
Our findings indicate that chemerin may play a role in advancing OSCC progression by increasing production of IL-6 and TNF-α, perhaps via a mechanism involving STAT3 signaling.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CSF2 (Colony stimulating factor 2) • IL15 (Interleukin 15)
1d
Inflammatory cytokines mediating the effect of oral lichen planus on oral cavity cancer risk: a univariable and multivariable mendelian randomization study. (PubMed, BMC Oral Health)
This study not only elucidates the potential causal relationship between OLP and the risk of OCC but also highlights the pivotal mediating role of IL-13 in this association.
Journal
|
IL13 (Interleukin 13)
1d
Inhibition of Oral Tumorigenesis by Antitumor B (clinicaltrials.gov)
P1, N=14, Recruiting, Medical College of Wisconsin | N=28 --> 14 | Trial primary completion date: May 2025 --> Sep 2024
Enrollment change • Trial primary completion date
1d
Expression Profile of Circulating Exosomal microRNAs in Leukoplakia, Oral Submucous Fibrosis, and Combined Lesions of Leukoplakia and Oral Submucous Fibrosis. (PubMed, Head Neck Pathol)
Plasma circulating exosomal miRNAs miRNA 21, miRNA 145, and miRNA 184 expression could be a novel panel of plasma biomarkers to categorise case group (leukoplakia, OSMF, leukoplakia and OSMF) patients with a high risk of malignant transformation.
Journal
|
MIR21 (MicroRNA 21)
2d
LRRC59 promotes the progression of oral squamous cell carcinoma by interacting with SRP pathway components and enhancing the secretion of CKAP4-containing exosomes. (PubMed, Heliyon)
We also revealed that the LRRC59-CKAP4 axis was a crucial regulator of CKAP4-containing exosome secretion in OSCC cells for migration and invasion. Therefore, based on our findings, LRRC59 may serve as a potential biomarker for OSCC patients, and LRRC59-induced exosome secretion via the CKAP4 axis may serve as a potential therapeutic target for OSCC.
Journal
|
CKAP4 (Cytoskeleton Associated Protein 4)
2d
Reproductive factors and risk of lung cancer among 300,000 Chinese female never-smokers: evidence from the China Kadoorie Biobank study. (PubMed, BMC Cancer)
Oral contraceptive use was associated with an increased risk of lung cancer in Chinese female never-smokers. Further studies are needed to assess lung cancer risk related to different types of oral contraceptives in similar populations.
Journal
|
CKB (Creatine Kinase B)
2d
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov)
P2, N=30, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Apr 2024 --> Dec 2024
Trial completion date
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
3d
Inhibin A contributes to the tumorigenesis of oral squamous cell carcinoma by KIAA1429-mediated m6A modification. (PubMed, J Oral Pathol Med)
Inhibin A promotes the tumorigenesis of oral squamous cell carcinoma by KIAA1429-mediated N6-methyladenosine modification. This study adds to our current knowledge of the molecular mechanisms underlying oral squamous cell carcinoma malignancy.
Journal
|
VIRMA (Vir Like M6A Methyltransferase Associated)
3d
Ginsenoside Rb1 Deters Cell Proliferation, Induces Apoptosis, Alleviates Oxidative Stress, and Antimetastasis in Oral Squamous Carcinoma Cells. (PubMed, Appl Biochem Biotechnol)
OSCC administration significantly reduced the levels of SOD, GSH, GPx, and CAT, increasing the levels of PCI-9A and PCI-13 cells, while GRb1 improved this situation. Therefore, we propose that Ginsenoside Rb1 could be an alternative therapeutic strategy for OSCC therapy.
Journal
|
PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • ANXA5 (Annexin A5)
3d
Expression of Aberrant MicroRNAs and p16INK4a Associated with HPV (6, 11, 16, 18, 31, 33, 35, 42, 43, 44, 45, 52, 53, and 56) in Oral Dysplasia and Squamous Cell Carcinoma: A Retrospective Study. (PubMed, Turk Patoloji Derg)
MiRNA-21, miRNA-22, and miRNA-224, besides p16 INK4a, could be used as indicators for HPV-associated OD and OSCC as their expression is attributed to the HPV oncoprotein. Further studies using follow-up data should be done to correlate it with miRNA overexpression.
Retrospective data • Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MIR21 (MicroRNA 21)
3d
LncRNA RASAL2-AS1 promotes METTL14-mediated m6A methylation in the proliferation and progression of head and neck squamous cell carcinoma. (PubMed, Cancer Cell Int)
Our study highlights the functional importance of the LncRNA RASAL2-AS1 in HNSCC and might assist in the development of a prognostic stratification and therapeutic approach. Which regulates HNSCC with the dependence of m6a manner.
Journal
|
METTL14 (Methyltransferase 14)
3d
The upregulation of VGF enhances the progression of oral squamous carcinoma. (PubMed, Cancer Cell Int)
This study highlights the multifaceted role of VGF in OSCC pathogenesis and introduces the miR-432-5p-VGF-IL23R regulatory axis as a critical mediator. The combined expression of VGF and IL23R emerges as a potent predictor of survival in oral carcinoma cases, suggesting potential implications for future therapeutic strategies.
Journal
|
MIR432 (MicroRNA 432)
3d
Comparative response to PDT with methyl-aminolevulinate and temoporfin in cutaneous and oral squamous cell carcinoma cells. (PubMed, Sci Rep)
Therefore, we propose that intracellular localization of GSK3β could be a good marker of response to PDT in HNSCC. Although the molecular mechanism of response to PDT needs further elucidation, this work shows that the most MAL-resistant line of CSCC is more sensitive to Temoporfin.
Journal
|
GSK3B (Glycogen Synthase Kinase 3 Beta)
|
Foscan (temoporfin)
3d
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) (clinicaltrials.gov)
P2, N=43, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial primary completion date: Sep 2023 --> Sep 2024
Trial primary completion date • Combination therapy
|
carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel
3d
Human Papillomavirus-Attributable Head and Neck Cancers in India-A Systematic Review and Meta-Analysis. (PubMed, JCO Glob Oncol)
The HPV-attributable fraction is considerably lower for OC, suggesting a negligible causative role of HPV in OC. A significant proportion of OPC and LC are attributed to HPV; however, their exact causative role is unclear because of the presence of other known risk factors.
Retrospective data • Review • Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
4d
RUVBL1 accelerates tongue squamous cell carcinoma by mediating CRaf/MEK/ERK pathway. (PubMed, iScience)
Overexpressing RUVBL1 enhanced the viability, wound healing percentage, invasion, sphere formation, angiogenesis, and resistance to cisplatin and 5-fluorouracil in CAL-27 and SCC-4 cells, and the opposite results were obtained by knocking down RUVBL1. In conclusion, RUVBL1 contributes to the malignant biological behavior of TSCC via activating the CRAF/MEK/ERK pathway. This provides molecular mechanisms and perspectives for targeted therapy of the CRAF/MEK/ERK pathway.
Journal
|
RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • RUVBL1 (RuvB Like AAA ATPase 1)
|
cisplatin • 5-fluorouracil
4d
High expression of ACTL6A leads to poor prognosis of oral squamous cell carcinoma patients through promoting malignant progression. (PubMed, Head Neck)
ACTL6A expressed higher in OSCC than normal samples and it could be used as an independent prognostic marker in OSCC patients.
Journal
|
TP53 (Tumor protein P53) • TP63 (Tumor protein 63) • MIR381 (MicroRNA 381) • E2F7 (E2F Transcription Factor 7)
|
TP53 mutation
5d
Unraveling the Genetic Web: H-Ras Expression and Mutation in Oral Squamous Cell Carcinoma-A Systematic Review. (PubMed, Head Neck Pathol)
This review sheds light on the prevalence of H-Ras mutations, their association with clinical characteristics, and their potential implications for OSCC prognosis. It also enhances our comprehension of the molecular mechanisms that underlie OSCC and paves the way for further research into targeted treatments based on H-Ras alterations.
Review • Journal
|
RAS (Rat Sarcoma Virus)
|
RAS mutation
|
Zarnestra (tipifarnib)
6d
Simultaneous disturbance of NHE1 and LOXL2 decreases tumorigenicity of head and neck squamous cell carcinoma. (PubMed, Auris Nasus Larynx)
This study demonstrated the possibility of achieving efficient anti-tumor effects by simultaneously disturbing multiple factors involved in the modification of the tumor microenvironment.
Journal
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LOXL2 (Lysyl Oxidase Like 2)
|
PD-1 positive
6d
Immune checkpoint CD161/LLT1-associated immunological landscape and diagnostic value in oral squamous cell carcinoma. (PubMed, J Pathol Clin Res)
Interestingly, treatment of OSCC patients with nivolumab (anti-PD-1) could restore tumoral CD161/LLT1 signal...More LLT1TC at the invasive front was another risk characteristic of exhausted T cells. In conclusion, in view of this heterogeneity, the LLT1/CD161 distribution pattern should be determined before CD161-based immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • FOXP3 (Forkhead Box P3) • KLRB1 (Killer Cell Lectin Like Receptor B1)
|
CD8 expression
|
Opdivo (nivolumab)
7d
Expression and clinical significance of NEK2 and EMT related molecules in oral squamous cell carcinoma (PubMed, Shanghai Kou Qiang Yi Xue)
NEK2 can be used as a prognostic marker for OSCC. The up-regulation of NEK2 and the changes in the expression levels of EMT related molecules can promote the occurrence and development of OSCC.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • NEK2 (NIMA Related Kinase 2)
|
CDH1 expression • VIM expression
7d
Study on the molecular mechanism of circ_0000326 regulating the proliferation, invasion and migration of oral squamous cell carcinoma HSC3 cells by targeting miR-567 (PubMed, Shanghai Kou Qiang Yi Xue)
Interference with the expression of circ_0000326 could reduce the ability of OSCC cell proliferation, colony formation, migration and invasion by promoting the expression of miR-567.
Journal
|
CDH1 (Cadherin 1) • CDH2 (Cadherin 2)
|
CDH1 expression
7d
Exploring prognostic microbiota markers in patients with endometrial carcinoma: Intratumoral insights. (PubMed, Heliyon)
This study emphasizes the microbiota's role in tailoring immunotherapy, offering a novel perspective in the treatment and prognosis of endometrial cancer. Significantly, our study's expansive sample analysis from the TCGA-UCEC cohort, employing linear discriminant analysis effect size methodology, not only validates but also enhances our understanding of the microbiota's role in endometrial cancer, paving the way for novel diagnostic and therapeutic approaches in its management.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L2 (Programmed Cell Death 1 Ligand 2)
7d
Heat-killed Prevotella intermedia promotes the progression of oral squamous cell carcinoma by inhibiting the expression of tumor suppressors and affecting the tumor microenvironment. (PubMed, Exp Hematol Oncol)
Taken together, our results suggest that P. intermedia could inhibit the expression of tumor suppressors, alter the tumor microenvironment, and promote the progression of OSCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A)
7d
MCC-19178: Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P1/2, N=95, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Mar 2024 --> Aug 2024
Trial completion date • Metastases
|
Opdivo (nivolumab) • Erbitux (cetuximab)
8d
Sensitization of cancer cells to paclitaxel-induced apoptosis by canagliflozin. (PubMed, Biochem Pharmacol)
It has been demonstrated that selective SGLT2 inhibitors, such as canagliflozin and dapagliflozin, display anticancer activity. Furthermore, canagliflozin downregulated cyclin B1 and phospho-BUBR1 upon spindle assembly checkpoint (SAC) activation by paclitaxel, and may consequently impair SAC. Thus, paclitaxel disturbed microtubule dynamics and canagliflozin compromised SAC activity, together they may induce premature mitotic exit, accumulation of aneuploid cells with DNA damage, and ultimately apoptosis.
Journal
|
BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CCNB1 (Cyclin B1)
|
paclitaxel • Farxiga (dapagliflozin)
8d
Biofeedback Rehabilitation to Improve Speaking and Eating in Public (clinicaltrials.gov)
P=N/A, N=34, Completed, University Health Network, Toronto | Recruiting --> Completed | N=66 --> 34
Trial completion • Enrollment change
8d
Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD-L1-expressing head and neck cancer. (PubMed, Mol Oncol)
Furthermore, the antitumor effect of ICB monotherapy was superior to those of other therapeutic agents, including cisplatin and inhibitors of vascular endothelial growth factor receptor 2 (VEGFR2)...In summary, ICB monotherapy is sufficient to induce TME normalization in the syngeneic model; the type I interferon pathway is indispensable in realizing the effects of ICBs. Furthermore, these results explain the underlying mechanism of the efficacy of ICB monotherapy against PD-L1-expressing HNSCC in the KEYNOTE-048 trial.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin
8d
Prognostic Significance of Serum Interleukin-6 Levels in Oral Squamous Cell Carcinoma. (PubMed, Cureus)
Regarding the correlation between blood tests and serum IL-6 levels, a strong positive correlation was observed between inflammatory responses and nutritional factors. Conclusion These results suggest that serum IL-6 may be a prognostic factor for metabolic abnormalities in patients with OSCC and that aggressive nutritional interventions may contribute to prognosis.
Journal
|
IL6 (Interleukin 6)
|
IL6 expression
8d
Notch signaling genes and CD8+ T-cell dynamics: Their contribution to immune-checkpoint inhibitor therapy in oral squamous cell carcinoma: A retrospective study. (PubMed, Cancer Med)
Four of 10 patients were positive for PD-L1 and CD8+ T. By analyzing WES in three of these four patients, we notably identified the mutations of NOTCH1, FBXW7, and noncoding RNA intronic mutation in NOTCH2NLR in two of these three patients. This study may enable better selection of ICI therapy with CD8+ T-cell infiltration via PD-L1 expression for oral squamous cell carcinoma patients with mutations in Notch signaling pathway.
Retrospective data • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • NOTCH1 (Notch 1) • CD8 (cluster of differentiation 8) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
|
PD-L1 expression • NOTCH1 mutation • NOTCH2 mutation • NOTCH mutation